Due to the limitations present in conventional markers, non-traditional biomarkers (such as NGAL, IL-6, IL-18, KIM-1, L-FABP, TIMP-2, IGFBP7, syndecan-1, and nephrin) have become a necessity in the early diagnosis of AKI in newborns with sepsis, so that death rates, length of hospitalization, and the incidence of future complications are decreased. This evidence concerns the gene IL6 and Sepsis.